Patient-centric structural determinants of adherence rates among asthma populations: Exploring the potential of patient activation and encouragement tool TRUSTR to improve adherence by Zia, Asim et al.
University of Vermont 
ScholarWorks @ UVM 
College of Agriculture and Life Sciences Faculty 
Publications College of Agriculture and Life Sciences 
1-1-2020 
Patient-centric structural determinants of adherence rates among 
asthma populations: Exploring the potential of patient activation 
and encouragement tool TRUSTR to improve adherence 
Asim Zia 







Judith J. Stephenson 
HealthCore Incorporated Wilmington 
See next page for additional authors 
Follow this and additional works at: https://scholarworks.uvm.edu/calsfac 
 Part of the Human Ecology Commons, and the Medicine and Health Commons 
Recommended Citation 
Zia A, Brassart A, Thomas S, Ye F, Stephenson JJ, Mullins CD, Jones CA. Patient-Centric Structural 
Determinants of Adherence Rates Among Asthma Populations: Exploring the Potential of Patient 
Activation and Encouragement Tool TRUSTR to Improve Adherence. Journal of health economics and 
outcomes research. 2020;7(2):111. 
This Article is brought to you for free and open access by the College of Agriculture and Life Sciences at 
ScholarWorks @ UVM. It has been accepted for inclusion in College of Agriculture and Life Sciences Faculty 
Publications by an authorized administrator of ScholarWorks @ UVM. For more information, please contact 
donna.omalley@uvm.edu. 
Authors 
Asim Zia, Arthur Brassart, Sheila Thomas, Fen Ye, Judith J. Stephenson, C. Daniel Mullins, and Christopher 
A. Jones 
This article is available at ScholarWorks @ UVM: https://scholarworks.uvm.edu/calsfac/183 
Zia A, Brassart A, Thomas S, et al. Patient-centric structural determinants of adherence 
rates among asthma populations: exploring the potential of patient activation and 
encouragement tool TRUSTR to improve adherence. JHEOR. 2020:7(2);111-122.
doi: 10.36469/jheor.2020.13607
Journal of Health Economics 
and Outcomes Research
Respiratory Diseases
Patient-Centric Structural Determinants of Adherence Rates Among Asthma 
Populations: Exploring the Potential of Patient Activation and Encouragement 
Tool TRUSTR to Improve Adherence
Asim Zia1,2*, Arthur Brassart2, Sheila Thomas3, Fen Ye3, Judith J. Stephenson4, C. Daniel Mullins5, Christopher A. Jones2,5 
1 Community Development and Applied Economics & Computer Science, University of Vermont, Burlington, VT, USA
2 trUSX, Inc., South Burlington, VT, USA
3 Sanofi, Inc., Bridgewater, NJ, USA
4 HealthCore Inc., Wilmington, DE, USA
5 Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy Baltimore, MD, USA 
ARTICLE INFROMATION
Article history: 
Received Feb 17, 2020
Received in revised form May 29, 2020
Accepted Jun 08, 2020
Keywords:
respiratory diseases, adherence rates, 
behavioral nudging, rewards, structural 
models, mobile health apps
*Corresponding author: 
E-mail address: asim.zia@uvm.edu
  Supplementary Material
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International 
License (CCBY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at 
http://creativecommons.org/licenses/by/4.0/legalcode for more information.
ABSTRACT
Background: Lack of adherence with prescribed medications among the asthma populations 
exacerbates health outcomes and increases social and economic costs.
Objectives: The proposed study aims to model patient-centric structural determinants of adherence 
rates among asthma patients and explore the potential of mobile health apps such as the TRUSTR 
platform to improve adherence using its power of monetary and non-monetary chatbotting and non-
monetary nudges. Following specific hypotheses are tested: (1) Patient attributes, such as their age and 
medical condition, have significant effect on their adherence with the prescribed treatment plans. (2) 
Behavioral nudging with rewards and engagement via mobile health apps will increase adherence rates.
Methods: The patient population (N = 37 359) consists of commercially insured patients with 
asthma who have been identified from administrative claims in the HealthCore Integrated Research 
Database (HIRD) between April 1, 2018 and March 31, 2019. Two Structural Equation Models 
(SEMs) are estimated to quantify direct, indirect, and total effect sizes of age and medical condition on 
proportion of days covered (PDC) and medical possession ratio (MPR), mediated by patient medical 
and pharmacy visits. Fourteen additional SEMs were estimated to lateralize TRUSTR findings and 
conduct sensitivity analysis. 
Results: HIRD data reveal mean adherence rate of 59% (standard deviation (SD) 29%) for PDC 
and 58% for MPR (SD 36%). Key structural findings from SEMs derived from the HIRD dataset 
indicate that each additional year in the age of the patient has a positive total effect on the adherence 
rate. Patients with poor medical condition are likely to have lower adherence rate, but this direct effect 
is countered by mediating variables. Further, each additional reward and higher engagement with a 
mobile app is likely to have a positive total effect on increasing the adherence rate.
Conclusions: HIRD data reveal mean adherence rate of 59% (SD 29%), providing the evidence for 
the opportunity to increase adherence rate by around 40%. Statistical modeling results reveal structural 
determinants, such as the opportunity to nudge, are higher among younger patients, as they have 
higher probability of being non-adherent. Methodologically, lateralization approach demonstrates the 
potential to capture real-world evidence beyond clinical data and merge it with clinical data. 
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BACKGROUND AND OBJECTIVES
Asthma is reported to affect 20.4 million adults over 18 in the US 
representing 8.3% of the adult population, with the number of newly 
diagnosed cases rising annually (+28% between 2001 to 2011). Nearly 
65% of adults with current asthma have persistent asthma accounting 
for considerable asthma morbidity, mortality, and costs. Each day, 
11 Americans die from asthma, and in 2015, 3615 people died from 
asthma. Adults are four times more likely to die from asthma than 
children.1 Lack of adherence with the prescribed medications by 
asthma patients is a significant factor in increasing mortality rates from 
asthma.2–6 Recent systematic review studies, however, have identified 
that there are significant gaps in understanding behavioral and socio-
economic drivers of non-adherence with prescribed medications.7,8 
While more quantitative studies are needed to understand the 
impact of non-adherence on the survival probabilities of asthma 
patients, improved understanding of the patient-centric structural 
determinants of adherence to prescribed treatments may provide 
actionable information to policy makers and relevant public and 
private sector stakeholders about the leverage points to maximize 
adherence rates among asthma patients accounting for their age, 
medical condition and the process of treatment (ER, hospitalization, 
specialist etc.). Furthermore, testing the impact of novel interventions 
to improve adherence rates, such as behavioral nudging through mobile 
health applications, could be more rigorously evaluated if the patient-
centric structural determinants of variable adherence rates among 
asthma patients are better understood. 
Fewer than 10% of all asthma clinical trials have included patient 
reported outcomes (PROs)  while delivering  more patient-centered 
care is the common objective of the industry. To reach the highest 
standard of patient-centered care, the deployment of engagement 
solutions, including the collection of PROs and patient insights during 
treatments, must be a priority.  Combining objective and subjective 
measures can  capture patient insights and experiences and  predict 
patients’ long-term treatment outcomes, health status, quality of life, 
and provide a better understanding of the parameters of adherence 
for each patient. While engaging with patients during treatment has 
been a challenge in the past, new health mobile app technologies like 
TRUSTR can easily engage with patients during their treatment with 
very high response rates, and a continuous flow of both self-reported 
and wearable-corroborated data with AI chatbotting, nudge theory, 
and conversational surveys. This study aims to estimate the capacity 
of such technology to engage with patients, collect  patient insights 
and PROs, and improve adherence in a real-world setting accounting 
for patient-centric structural determinants of adherence rates.
Text messages have been shown to be highly effective and cost-
effective at reaching patients outside of the hospital setting. Recently, 
there has been great interest in the “beyond the pill” or “beyond the 
point of infusion” area of the conversational patient experience. These 
include daily reminders to stay adherent or the offering of personalized 
motivational texts that can include words of recognition. Each of these 
touch points can augment treatment experience in a positive way, such as 
improving adherence rates, to be interpreted in their aggregate toward a 
wide range of value added for public and private sectors. Han and Lee9 
conducted a systematic review of 20 randomized, controlled trial (RCT) 
studies to examine the effectiveness of mobile health applications in 
changing health related behaviors and clinical health outcomes. They 
found that 16 out of these 20 studies reported a positive impact on the 
targeted health behavior or clinical health outcomes. These RCT studies 
focused on evaluating the impact of mobile health apps on changing 
health related behaviors such as physical activity,10,11 adherence rate,12,13 
dietary change,14 weight loss,15,16 smoking cessation,17 and alcohol 
addiction.18 Another meta-analysis study19 evaluated 9 RCTs with 
1159 subjects to quantify efficacy of app-based interventions designed 
to support medication adherence and investigate which behavior 
change techniques used by the apps are associated with efficacy. In 
the sampled RCTs, health conditions of target populations included 
cardiovascular disease, depression, Parkinson’s disease, psoriasis, and 
multimorbidity. This study found that patients who use mobile apps 
to support them in taking medications are more likely to self-report 
adherence to medications. However, the meta-regression of behavioral 
change techniques did not reveal any significant associations with the 
effect size.
In this evolving socio-technological context, alongside text 
conversations, identifying activity levels using wearable tracking 
devices highlights an opportunity to collect persistent, intelligent 
patient reported outcomes (iPROs) by merging conversational chatbots 
with wearable-corroborated measurements. Continuous motivated 
adherence to medication and early reporting of treatable side effects 
are high priority areas of interest. Mobile health apps such as TRUSTR 
can potentially measure the treatment experience using the power 
of chatbotting, nudge theory, conversational surveys, and wearable-
corroborated data in a real-world setting.
This study models patient-centric structural determinants of 
adherence rates among asthma patients and explores the potential of 
mobile health apps such as TRUSTR platform to improve adherence 
using its power of chatbotting, monetary and non-monetary nudges, 
and conversational surveys. The identification of key variables and 
tendencies will help practitioners describe, understand, and predict the 
outcomes of a real-world setting use of TRUSTR in the population 
of interest. It will also yield insights into ways by which to improve 
patient adherence and patient satisfaction. The following two specific 
hypotheses are tested in this study:
1. Patient attributes, such as age and medical condition, have 
significant effect on their adherence with the prescribed treatment 
plans: 
a. Older patients are more likely to have higher adherence rates 
than younger patients and
b. Patients suffering from severe medical conditions are likely 
to have lower adherence rate, and
2. Compared with a non-TRUSTR lateralized database control, 
behavioral nudging with rewards and engagement through 
chatbotting through mobile health apps such as TRUSTR will 
increase adherence rates.
METHODS
Measurement of Adherence Rates
Adherence rate is generally measured using two approaches: medical 
possession ratio (MPR)20–22 and proportion of days covered (PDC).6,23–
25 There is no single statistical definition for MPR and various MPR 
calculations have been developed and discussed in the literature.26 The 
MPR value determines the proportion of days of medication supply 
within a time interval and both fixed and variable time intervals have 
been used. We used a variable time interval to accommodate covariance 
analysis described in SEM methodology. Specific definitions of MPR 
and PDC used in this study are provided as follows. 
Medical possession ratio (MPR) is defined as the total number 
of treated days in the specified time period divided by total number of 
days from first treated day until the last treated day (including the last 
Rx day supply). In this study, MPR is only calculated among patients 
that have two or more fills with the specified medications over the 
specified period; MPR of patients with only one fill with the specified 
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medications is coded as ‘0’.
MPR =
total Rx days of supply
total days in observation period from rst until last treated day
 
PDC uses all available data for a given patient (i.e. from index 
until the end of continuous eligibility) and is calculated as the total 
number of covered days on a medication during the time period from 
index until the end of study observation period, divided by the total 
number of days in observation period from first until last treated day.
PDC=
total covered days on drug(s) in study period
total days in observation period from rst until last treated day 
 
We used both measures, MPR and PDC, with variable time 
measures to estimate the adherence rate in this study. 
Patient-Centric Data of Adherence Rates Among Asthma Patients
The data source for this study is the HealthCore Integrated Research 
Database® (HIRD). The HIRD is a large administrative health care 
database maintained by HealthCore for use in health outcomes and 
pharmacoepidemiologic research. The HIRD contains a broad, clinically 
rich and geographically diverse spectrum of longitudinal medical and 
pharmacy claims data from 14 Anthem-affiliated health plans in the 
Northeastern, Mid-Atlantic, Southeastern, Midwest, Central, and 
Western regions of the United States and represents members in each 
of the 50 states. The database includes lines of business such as health 
maintenance organizations, point of service plans, preferred provider 
organizations, Medicare Advantage, consumer directed health plans, 
and indemnity plans. HIRD data on over 49 million patients are 
available from January 1, 2006, for all of the plans represented in the 
database.
For the HIRD sample presented in this study, the patient 
identification period is from April 1, 2018 to March 31, 2019 and 
patients are required to have continuous enrollment during that period. 
The sampled patient population consists of commercially insured 
patients with asthma who have been identified from administrative 
claims in the HIRD between April 1, 2018 to March 31, 2019 (patient 
identification period) and meet the following inclusion criteria: 
1. At least one medical claim with an ICD-10-CM diagnosis code 
for moderate or severe persistent asthma (J45.4x or J45.5x) 
during the patient identification period from April 1, 2018, to 
March 31, 2019,
2. At least one pharmacy claim for an inhaled corticosteroid (ICS) 
or at least one pharmacy claim for a long-acting beta-2 adrenergic 
agonist (LABA) or at least one pharmacy claim for an ICS/LABA 
combo medication (See Supplementary Materials, Table S2 for 
specific medication names and generic product identifier codes),
3. Have only commercial health insurance during April 1, 2018, to 
March 31, 2019,
4. Are 18 years of age or older as of the end of the patient 
identification period (March 31, 2019), and 
5. Have at least 12 months of continuous enrollment with both 
medical and pharmacy benefits during the patient identification 
period.
The number of patients, means, SD, standard errors (SE), 
medians, correlation and covariance matrices were provided for ten 
asthma-related claims-determined variables described in Table 1 for 
the patient identification period from April 1, 2018, to March 31, 
2019. All study measures of interest were described using univariate 
statistics consisting of number of patients, mean, SD, SE, and median. 
The patient cohort was limited to patients with at least one medical 
claim with an ICD-10-CM asthma diagnosis in any position and at 
least one pharmacy claim for an ICS, LABA, or ICS/LABA combo 
medication in the 12 month period from April 1, 2018 to March 31, 
2019. The correlation and covariance matrices for the study measures 
were determined for the identified patient cohort; all study variables 
were considered to be continuous and there were no missing values for 
any of them. All variables were included, except inpatient length of stay 
(LOS), which was presented descriptively since it was calculated only 
for those patients with at least one inpatient hospitalization. Table 2 
and Table 3 show means, variances, and covariances of 10 variables that 
were used to estimate Summary Statistics Data (SSD) in STATA 15.
 
SEMs Estimated from Summary Statistics Databases (SSDs)
STATA 15 SSD commands were used to reconstruct the dataset and 
measure 16 SEMs. SEMs #1 and #2 were measured to predict MPR and 
PDC respectively directly from the HIRD dataset. Data analysis was 
performed using structural equation modeling logarithms in STATA 
15 for Windows (StataCorp LLC, College Station, TX) specifically 
following SEM algorithms developed by Acock28 and Ullman and 
Bentler.29
Goodness-of-fit statistics were used to determine the fit of the 
estimated SEMs to the sample data. Two approaches to measure the 
goodness of fit were utilized for evaluating the model fit of estimated 
SEMs: Standardized Root Mean-squared Residual (SRMR) and 
Coefficient of Determination (CD). Ideally, the best fit models have 
SRMR closer to zero and CD closer to one. SRMR and CD for all 16 
SEMs are reported in the Supplementary Materials. Since SEMs were 
derived from SSD, we could not use other statistics (e.g., likelihood 
ratio tests, comparative fit index, Tucker-Lewis index) to evaluate the 
model fitness. 
Lateralization of TRUSTR Social Media Experimental Findings 
to Modeling Patient-Centric Adherence Rates
Tables 2 and 3 show the addition of two variables (shown in red 
font), rewards [measured as $/month] and engagement rate [measured 
as text messages/month] that were lateralized from TRUSTR social 
media study (see Zia et al27) to explore the potential of mobile health 
apps on adherence rates. We assume that rewards are distributed with a 
mean of $30 per month and SD of $15. We assume baseline covariance 
rates of 0.7 and 0.6 between rewards and MPR, and PDC respectively. 
Further, we assume that respondents send a mean of 234 text messages 
per month with an SD of 180 messages per month. Consistent with the 
social media study, we assume a high covariance of 0.82 between rewards 
and engagement rate. We also assume baseline covariance rates of 0.5 
and 0.46 between engagement rate and MPR, and PDC respectively. 
Four sensitivity analysis scenarios are also tested, with two scenarios (S1 
and S2) representing 10% and 20% increases in covariance of rewards 
and engagement rate with adherence rate measures (MPR and PDC), 
and two scenarios representing 10% and 20% decreases in covariance 
of rewards and engagement rate with adherence rate measures (See 
Table 4 for scenarios representing sensitivity analysis). SEMs #3 and 
#4 measure the effect of rewards on MPR and PDC respectively; SEMs 
#5 and #6 measure the effect of engagement rate on MPR and PDC 
respectively; and SEMs #7 and #8 measure the effect of both rewards 
and engagement rate on MPR and PDC respectively. Finally, we 
present results of sensitivity analysis through eight additional SEMs, 
four of which vary covariance between rewards and engagement rate 
vis-à-vis adherence rate measure of MPR, and the other four for PDC 
by 10% and 20% increases or decreases in covariance, compared with 
baseline covariance rates assumed in SEMs #7 and #8. 
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Table 1. Study Variables
Name in the Protocol Name in the Model Code Description
Age age Age in years at end of patient identification period.
Inpatient Hospitalizations inpatient_hospitaliza~s Number of inpatient hospitalizations (including ER visits that lead 
to a hospitalization); no inpatient hospitalization is coded as ‘0’
LOS among patients with >1 asthma-related hospitalization; 
aggregated over period of interest (days), mean (SE), median.
ER Visits er_visits        Number of ER visits; no ER visit is coded as ‘0’.
Primary Care Physician (PCP) [Family 
Medicine/Practice, Internal Medicine, 
Gerontologist] Office Visits
pcp_officevisits    Number of Primary Care Physician (PCP) [Family Medicine/
Practice, Internal Medicine, Gerontologist] office visits; no visit is 
coded as ‘0’.
Specialist (Allergy/Immunology, 
Pulmonology, Respiratory) Office Visits
specialist_office_vis~s Number of Specialist (Allergy/Immunology, Pulmonology, 
Respiratory) office visits; no visit is coded as ‘0’.
Other Outpatient Services other_outpatientservi~s Number of other outpatient services (e.g., durable medical 
equipment, imaging, medication and related services, procedures, 
physical therapy/occupational therapy/speech, physician other 
services, lab tests, other); no other outpatient services is coded as 
‘0’.
Asthma-Related Pharmacy Dispensing pharmacy_fills     Asthma-related pharmacy dispensing (n[%] of patients with 
≥1 prescription fill for all medications listed in Supplementary 
Material, Table S2; mean [SE]/median of fills among all patients) 
(refer to Supplementary Material, Table S2 for codes).
Medical Possession Ratio (MPR) mpr Medical possession ratio (MPR) for ICS, LABA, and ICS/LABA 
combo medications (n[%] of patients with ≥1 prescription 
fill; mean [SE]/median of fills among all patients) (refer to 
Supplementary Material, Table S2 for codes). MPR is defined as 
total number of treated days in the specified time period divided by 
total number of days from first treated day until the last treated day 
(including the last Rx day supply). MPR is only calculated among 
patients that have two or more fills with the specified medications 
over the specified period; MPR of patients with only one fill with 
the specified medications is coded as ‘0’. 
Proportion of Days Covered (PDC) pdc Proportion of days covered (PDC) for ICS, LABA, and ICS/
LABA combo medications (n[%] of patients with ≥1 prescription 
fill; mean [SE]/median of fills among all patients) (refer to 
Supplementary Materail, Table S2 for codes). PDC is defined as 
total number of treated days in the specified time period divided 
by total number of days from first treated day until the end of the 
period. Calculated only among those patients who received one or 
more of the specified medication(s) over the specified period.
Quan-Charlson Comorbidity Index 
(QCI) score
qci_score Quan-Charlson comorbidity index (QCI) score; n of patients; 
mean (SE), median (refer to Supplementary Material, Table S3 for 
codes)
To quantify comorbidity, the QCI score is computed by adding 
the weights that are assigned to the specific diagnoses. A score of 
1 is attributed to myocardial infarction, congestive heart failure, 
peripheral vascular disease, cerebrovascular disease, dementia, 
chronic pulmonary disease, connective tissue/rheumatologic 
disease, peptic ulcer disease, mild liver disease, and diabetes without 
chronic complications. The following diseases are scored as 2: 
hemiplegia or paraplegia, renal disease, diabetes with complications, 
and malignancy including leukemia and lymphoma. Moderate or 
severe liver disease is scored 3. Finally, a score of 6 is assigned to 
metastatic solid carcinoma and AIDS/HIV. Each diagnosis is only 
counted once (e.g., if a patient has ICD-9 code 410.xx and 412.xx, 
they will receive a score of 1 for MI, not 2). The minimum possible 
score is 0 and the maximum possible score is 33.
115Zia A, et al.
JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH
Table 2. Means and Medians for HIRD Data and Two Lateralization Variables, Rewards, and Engagement Rate Derived from the 
TRUSTR Social Media Study27
Variable Number (n%)
Analysis  
Sample Size Mean SD SE Median
Age on 03/31/2019 37 359 (100.0%) 37 359 49.64 14.87 0.0769 52
Inpatient Hospitalizations 1133 (3.0%) 37 359 0.04 0.26 0.0013 0
Length of Stay (LOS) among 
patients with >1 asthma-related 
hospitalization
1133 (3.0%) 1133 5.61 6.80 0.2020 4
ER Visits 684 (1.8%) 37 359 0.02 0.20 0.0010 0
Out visits 36 789 (98.5%) 37 359 3.18 4.73 0.0245 2
PCP Office Visits 12 883 (34.5%) 37 359 2.18 2.50 0.0129 1
Specialist Office Visits 18 987 (50.8%) 37 359 2.61 3.81 0.0197 2
Other Outpatient Services 26 740 (71.6%) 37 359 2.22 4.41 0.0228 1
Pharmacy Fills (All meds in table 2) 37 359 (100.0%) 37 359 9.95 7.37 0.0381 8
Pharmacy Fill (ICS, LABA, ICS/LABA) 37 359 (100.0%) 37 359        
ICS Monotherapy 10 571 (28.3%) 37 359        
LABA 371 (1.0%) 37 359        
ICS/LABA combination 30 590 (81.9%) 37 359        
Quan-Charlson Comorbidity Index 
(QCI) score 37 359 (100.0%) 37 359 1.47 1.13 0.0058 1
MPR (ICS, LABA, ICS/LABA) 37 359(100.0%) 37 359 0.58 0.36 0.0019 0.66
PDC (ICS, LABA, ICS/LABA) 37 359 (100.0%) 37 359 0.59 0.29 0.0015 0.60
Reward 37 359 37 359 30 15 0.1 35
Engagement rate (messages/month) 37 359 37 359 234 180 0.18 265
116 Zia A, et al.
JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH























Age 221.105233 0.089650 -0.094017 2.442816 3.267802 5.864529 14.209445 4.632682 0.803770 0.761121
Inpatient Hospitalization 0.089650 0.067846 0.011868 0.037303 0.033255 0.113002 0.200045 0.036237 0.000065 -0.000166
ER Visits -0.094017 0.011868 0.040578 0.033435 0.022245 0.075032 0.084031 0.002199 -0.001100 -0.000795
PCP Office Visits 2.451662 0.037385 0.033620 6.244202 6.816085 7.943561 4.400360 0.101140 0.087750 0.047842
Specialist Office Visits 3.267802 0.033255 0.022245 6.805591 14.548804 15.837080 7.174931 0.076749 0.131478 0.073374
Outpatient Services 5.864529 0.113002 0.075032 7.918511 15.837080 22.331055 10.065882 0.274862 0.182628 0.105173
Pharmacy (Asthma meds) 14.209445 0.200045 0.084031 4.385411 7.174931 10.065882 54.346633 0.771759 1.037027 0.708629
QCI Score 4.632682 0.036237 0.002199 0.101364 0.076749 0.274862 0.771759 1.282943 0.018688 0.012082
MPR (ICS, LABA, ICS/
LABA) 0.803770 0.000065 -0.001100 0.087459 0.131478 0.182628 1.037027 0.018688 0.129239 0.062483
PDC (ICS, LABA, ICS/
LABA) 0.761121 -0.000166 -0.000795 0.047573 0.073374 0.105173 0.708629 0.012082 0.062483 0.082140
Rewards -0.2 -0.8 -0.6 0.05 0.1 0.15 0.85 0.002 0.7 0.6 225
Engagement rate 
(messages/month) -0.100000 -0.600000 -0.7 0.08 0.2 0.26 1.04 0.001 0.5 0.46 0.82 32 400
ER=Emergency Room; PCP=Primary Care Physician; QCI=Quan-Charlson Comorbidity Index; MPR=Medication Possession Ratio; PDC=Proportion of Days Covered
ICS=Inhaled corticosteroid; LABA=Long acting beta-2 adrenergic agonist
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Table 4. Scenarios Representing Sensitivity Analysis on 
Covariance of Rewards and Engagement Rate With Adherence 




Engagement Rate 0.5 0.46
Senstivity analysis 10% higher covariance (S1)
MPR PDC
Rewards 0.77 0.66
Engagement Rate 0.55 0.506
Senstivity analysis 20% higher covariance (S2)
MPR PDC
Rewards 0.84 0.72
Engagement Rate 0.6 0.552
Senstivity analysis 10% lower covariance (S3)
MPR PDC
Rewards 0.63 0.54
Engagement Rate 0.45 0.414
Senstivity analysis 20% lower covariance (S4)
MPR PDC
Rewards 0.56 0.48
Engagement Rate 0.4 0.368
RESULTS
Estimated SEMs for eight models are presented in the Supplementary 
Material (Appendix 2). The direct, indirect, and total effects of each 
SEM are also presented in the Supplementary Material (Appendix 
2). Furthermore, results from eight additional SEMs estimated for 
four sensitivity analysis scenarios are reported in the Supplementary 
Material (Appendix 3), and their highlights are also summarized. 
Next, we focus on presenting the key findings with respect to the study 
objectives and hypotheses.
Figure 1 and Figure 2 show statistically significant paths estimated 
for SEMs 1 and 2, respectively.
Both of these SEMs show confounding effects of patient age 
and QCI score on MPR and PDC. Both models predict that each 
additional year in the age of the patient has a direct positive effect on 
the adherence rate. Age also influences adherence rate through various 
indirect pathways, as shown in Figures 1 and 2. Older people are less 
likely to have inpatient hospitalizations and ER visits (connected with 
asthma), and asthma patients going through inpatient hospitalizations 
and ER visits are likely to have lower adherence rates (both MPR and 
PDC). Conversely, older people are more likely to maintain their 
pharmacy fills, which in turn has a positive effect on adherence rates. 
Further, we also find that older people are more likely to engage in 
PCP office visits, specialist office visits, and utilize other outpatient 
services, but we do not detect any significant effect of these mediating 
variables on adherence rates (with the exception of PCP office visits 
having positive effect on MPR). When we combine direct and indirect 
effects, age has consistently positive effect on adherence rate, implying 
that younger people are less likely to adhere with prescribed asthma 
medications (see Table 5 for total effects of eight SEMs). 
Similarly, medical condition of the patients, measured through 
QCI, also have confounding effects on adherence rates, mediated 
through variegated health management pathways. Structural analysis in 
Figures 1 and 2 also shows that, as expected, patients with worse medical 
conditions are more likely to engage in inpatient hospitalizations, ER 
visits, PCP office visits and other outpatient services, which in turn 
have differential effects on adherence rates. The direct effects of medical 
conditions on adherence rates are statistically significant in both SEMs: 
patients with worse medical conditions are less likely to adhere. Overall, 
from total effects analysis shown in Table 5, we find that patients with 
worse medical condition (depicted by higher QCI score) have lower 
adherence rate (significant for PDC at p<0.05, but not significant for 
MPR). 
Six additional SEMs were estimated to lateralize TRUSTR 





































Only statistically significant paths are shown.
* 90% confidence level; ** 95% confidence level; *** 99% confidence level
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Only statistically significant paths are shown.
* 90% confidence level; ** 95% confidence level; *** 99% confidence level



















-0.0340*** -0.0303*** -0.0120** -0.0060 -0.0339*** -0.0302*** -0.0120** -0.0059
ER visits -0.0259*** -0.01914*** -0.0055 0.0034 -0.0258*** -0.0190*** -0.0054 0.0035
PCP office visits  0.01583** -0.0006*** 0.0136** -0.0031  0.0158** -0.0007 0.0136* -0.0031
Specialist office 
visits
-0.0107 -0.0093 -0.0014 0.0008 -0.0106 -0.0093 -0.0014 0.0008
Other Outpatient 
Services
 -0.0078 -0.0154  -0.0174* -0.0259** -0.0078 -0.0154 -0.0174* -0.0260**
Pharmacy fills  0.3844*** 0.3293*** 0.3812*** 0.3257*** 0.3844*** 0.3293*** 0.3812*** 0.3257***
Age 0.1486*** 0.1451*** 0.1489*** 0.1818*** 0.1486 0.1815*** 0.1489*** 0.1818***
QCI Score 0.0048 -0.0283*** 0.0048 -0.0129** 0.0048965  -0.0128** 0.0048 -0.0129**
Rewards N/A N/A 0.1297*** 0.1393*** N/A N/A 0.1297*** 0.1393***
Engagement Rate N/A N/A N/A N/A 0.0077 0.0088* 0.0076 0.0088*
* 90% confidence level; ** 95% confidence level; *** 99% confidence level
findings (i.e., “what if ” scenarios tested to quantify impacts of 
TRUSTR rewards and engagement nudges on behavioral change 
from one population (social media) to another population (HIRD)). 
Supplementary Materials show results for SEMs #3 through #6. Here, 
in Figure 3 and Figure 4 we show results from SEMs #7 and #8, each 
of which presents structural determinants for variables derived from 
HIRD data set as well as TRUSTR variables (rewards and engagement 
rate) that are hypothesized to influence adherence rates as mediated 
through health management pathways. Table 5 presents total effects 
for all eight SEMs. Further, sensitivity analysis around lateralization 
assumptions were conducted with eight additional SEMs, results of 
which are shown in Table 6. 
From Figures 3 and 4 and Table 5, we find that with lateralization, 
age has a consistently significant positive effect size across both MPR 
and PDC; however, QCI score has a negative effect only for PDC. 
Importantly, we find that each additional monetary reward increases 
the likelihood of adherence rate. The total effect of engagement rate 
is marginally positive for PDC but insignificant for MPR. Further, 
sensitivity analysis results shown in Table 6 demonstrate that generally 
the findings about structural determinants of adherence rates are 
robust across SEMs. The effects of rewards and engagement rate 
however predictably vary upward and downward, when we marginally 
increase (SEMs #9 through #12) or marginally decrease (SEMs #13 
through #16) the covariance between rewards and adherence rates 
or engagement rates and adherence rates. Remaining structural 
determinants of adherence rates retain the direction and magnitude of 
their effects, as estimated in SEMs #1 through #8. 
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Only statistically significant paths are shown.
* 90% confidence level; ** 95% confidence level; *** 99% confidence level


































Only statistically significant paths are shown.
* 90% confidence level; ** 95% confidence level; *** 99% confidence level
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DISCUSSION
HIRD data reveal a mean adherence rate of 59% (SD 29%), providing 
the evidence for the opportunity to increase adherence rate by around 
40%. Specifically, HIRD data reveal mean adherence rate of 59% (SD 
29%) for PDC and 58% for MPR (SD 36%). While PDC is typically 
considered to be more conservative estimate of medication adherence 
rate compared with MPR, the HIRD dataset reveals statistically similar 
mean value. The SD of MPR is however higher than PDC. The reason 
the mean MPR is slightly less than the mean PDC is because of the 
statistical definition of MPR that we used. As indicated earlier, there is 
no single statistical definition for MPR and various MPR calculations 
have been developed and discussed in the literature.26 The MPR value 
determines the proportion of days of medication supply within a time 
interval and both fixed and variable time intervals have been used. 
We used a variable time interval—the MPR denominator, is the total 
number of days from first treated day until the last treated day. This 
requires at least two fills and patients with only one fill were coded 
with an MPR of zero so that all 37 359 observations could be used for 
the covariance calculations. The statistical MPR and PDC definitions 
that were used are given in Table 1. The effect of the zero MPR’s on the 
mean reduces the mean MPR so that it is less than the average PDC; 
however, the median is unaffected by the 0 MPRs and the median 
MPR (0.66) > median PDC (0.60) (see Table 2). 
A key implication of this study is that statistical modeling 
results reveal structural determinants, which could be utilized to find 
substantial opportunities for increasing the adherence rates. First, 
structural analysis of HIRD data set reveals that the opportunity to 
nudge is higher among younger patients as they have higher probability 
of being non-adherent. Second, patients with relatively worse medical 
conditions could also be targeted for improving the overall adherence 
rates with asthma medications. 
Findings about structural determinants of adherence rates are 
also consistent with previously published empirical literature. For 
example, in a recent systematic review of 51 published studies focused 
on evaluating asthma inhaler adherence determinants in adults, Dima 
et al7 found “consistent links between adherence and stronger inhaler-
necessity beliefs, and possibly older age.” While our study did not 
explicitly model inhaler-necessity beliefs, as these are not available 
in HIRD data set, we found statistically significant effect of age on 
adherence, consistent with Dima et al.7 finding. Similar age effects on 
adherence rates were found by Feehan et al.6 Further, our structural 
findings about patient medical condition and health management 
interventions are also consistent with previous literature reviewed 
by Bårnes and Ulrik.5 A review of 19 studies revealed that the mean 
level of adherence was between 22% and 63%. “Poor adherence was 
associated with youth, being African-American, having mild asthma, 
<12 years of formal education, and poor communication with the 
health-care provider, whereas improved adherence was associated with 
being prescribed fixed-combination therapy (ICS and long-acting beta-
2 agonists). Good adherence was associated with higher FEV1, a lower 
percentage of eosinophils in sputum, reduction in hospitalizations, 
less use of oral corticosteroids, and lower mortality rate (Bårnes and 
Ulrik5).” 
Lateralization of structural findings from HIRD dataset, when 
merged with TRUSTR social media experimental study, identify 
potential pathways to capitalize on the opportunities available for 
targeting younger asthma patients and/or patients in relatively worse 
off medical condition. In our lateralization approach, we assumed 
fairly conservative assumptions, and then conducted sensitivity 
analysis around those conservative assumptions, and discovered that 
each additional TRUSTR reward has a positive total effect on nudging 
the adherence rate to be higher. Since many mobile health app studies 
have found evidence in the literature that younger people are more 
likely to use mobile health apps, deployment of mobile health apps to 
nudge the behaviors of younger people to be more complaint appears 
very promising.30–35 An RCT with a mobile health app (e.g., TRUSTR) 
would be the next logical step to test the potential of nudging younger 
asthma patients to become more adherent with their medications. In 
a recently published meta-analysis study, Armitage et al.19 found that 
mobile health apps increase medication adherence rates among the 
patients suffering from cardiovascular disease, depression, Parkinson’s 
disease, psoriasis, and multimorbidity. This study shows that similar 
benefits from mobile health apps could be derived for asthma patients. 
The nudging opportunity might not be as straightforward with 
the people suffering from relatively worse medical condition. Mere 
provision of rewards might not be enough to overcome the capacity 
limitations of severe asthmatic patients. Non-monetary nudging 
through conversational features of mobile health apps could however 
be tested in follow up RCT. Engaging younger patients through 
conversational and non-monetary engagement could also be tested in 
follow up RCTs. Existing telehealth applications fail to reach many 



















S3: 10% ↓ 
SEM #15 
(MPR)
S4: 20% ↓ 
SEM #16 
(PDC)
S4: 20% ↓ 
Inpatient
hospitalizations -0.0095* -0.0032 -0.007 -0.0005 -0.0145** -0.0086* -0.0169*** -0.0112**
ER visits -0.0030 0.0060 -0.0007 0.0085* -0.0077 0.0010 -0.0010** -0.0014
PCP office visits 0.0134** -0.0033 0.0131* -0.0036 0.0139** -0.0028 0.0141** -0.0025
Specialist office 
visits -0.0003 0.0019 0.0006 0.0031 -0.0024 -0.0002 -0.0035 -0.0013
Other Outpatient 
Services -0.0185* -0.02720** -0.0196* -0.0283** -0.0163 -0.0248** -0.0152 -0.0237**
Pharmacy fills 0.3809*** 0.3253*** 0.3805*** 0.3249*** 0.3816*** 0.3261*** 0.3819*** 0.3265***
Age 0.1489*** 0.1818*** 0.1489*** 0.1818*** 0.1488*** 0.1817*** 0.1488*** 0.1817***
QCI Score 0.0048 -0.0129** 0.0048 -0.0129** 0.0048 -0.0128** 0.0048 -0.0128**
Rewards 0.1427*** 0.1532*** 0.1557*** 0.1672*** 0.1167*** 0.1254*** 0.1038*** 0.1115***
Engagement Rate 0.0084* 0.0097* 0.0092* 0.0106** 0.0069 0.0079 0.0061 0.0070
* 90% confidence level; ** 95% confidence level; *** 99% confidence level
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patients, and fail to establish crucial elements of digital trust. Moreover, 
many concerns of patients from a real-world data perspective are missed 
by surveys that have very narrow response windows. The TRUSTR tool 
allows for multichannel controlled messaging while inviting crucial 
feedback in the patient’s own words. Moreover, by co-synchronizing 
and co-registering with wearables and other applications (WhatsApp, 
GoogleFit etc.), it is envisaged that TRUSTR can provide controlled 




This study models patient-centric structural determinants of adherence 
rates among asthma patients and explores the potential of mobile 
health apps such as TRUSTR platform to improve adherence. The US 
nationally representative HIRD data reveal mean adherence rate of 
59% (SD 29%) for PDC and 58% for MPR (SD 36%). Key structural 
findings from SEMs derived from the HIRD dataset indicate that: (1) 
Each additional year in the age of the patient has a positive total effect 
on the adherence rate. (2) Patients with worse medical condition (ie, 
higher QCI score) are likely to have lower adherence rate, but this 
direct effect is countered in opposite direction by mediating variables. 
Further, key findings from lateralization of TRUSTR with HIRD 
data indicate that: (3) Each additional reward has a positive total 
effect on increasing the adherence rate. (4) Higher engagement rate 
with TRUSTR app has a weak positive effect on increasing adherence 
rate. These findings indicate that the opportunity to nudge is higher 
among younger patients as they have higher probability of being 
non-adherent. Methodologically, lateralization approach pioneered in 
this study demonstrates the potential to capture real-world evidence 
beyond clinical data and merge it with clinical data (e.g., this study 
lateralizes TRUSTR experimental findings to a sample of 37 359 
asthma patients identified from claims in the HealthCore  Integrated 
Research Database® (HIRD) using structural equation modeling 
and path analysis). Statistical modeling demonstrates the ability to 
differentiate patient behaviors of interest with more granularity (e.g., 
by age, medical condition (QCI score), and frequency of visits to ER, 
specialists, PCPs, and other outpatient services). RCTs with mobile 
health apps (e.g., TRUSTR) are recommended for future research 
to test the potential of nudging (asthma) patients to become more 
adherent with their medications. 
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